Mechanisms of antipsychotic-induced weight gain

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 23, 2001, Pages 23-29

  McIntyre, R S ^a   Mancini, D A ^a   Basile, V S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; TOPIRAMATE;

BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; HUMAN; MORTALITY; OBESITY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREATMENT PLANNING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CYTOKINES; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; GONADAL STEROID HORMONES; HISTAMINE; HUMANS; LEPTIN; MALE; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; OBESITY; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0034795552     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Recent advances in basic obesity research
2. The spread of the obesity epidemic in the United States, 1991-1998
3. Antipsychotic-induced weight gain: A comprehensive research synthesis
4. Prevalence of overweight and obesity in bipolar patients
5. Anthropometry and adiposity in a group of people with chronic mental illness
6. The distribution of adipose tissue in female in-patients receiving psychotropic drugs
7. The association of medical comorbidity in schizophrenia with poor physical and mental health
8. Weight changes in relation to the characteristic of patients on chlorpromazine
9. Weight changes during treatment with phenothiazine derivatives
10. The effect of antipsychotic drugs on body weight: A retrospective review
11. Weight gain associated with antipsychotic drugs
12. Weight changes with depot neuroleptic maintenance therapy
13. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities
14. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months
15. Weight gain among schizophrenic patients treated with clozapine
16. Clozapine-induced weight gain: Prevalence and clinical relevance
17. Clozapine and weight gain
18. Differential effect of clozapine on weight: A controlled study
19. Weight gain induced by clozapine
20. Molindone in chronic schizophrenia
21. Molindone: A crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients
22. Weight reduction in schizophrenics by molindone
23. Novel antipsychotics: Comparison of weight gain liabilities
24. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
25. Antipsychotic agents and bipolar disorder
26. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder
27. Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics
28. Body weight and mortality among women
29. Weight change and atypical antipsychotic treatment in patients with schizophrenia
30. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
31. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
32. New onset diabetes and atypical antipsychotics
33. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
34. Atypical antipsychotic agents and diabetes mellitus
35. The treatment of unrelated disorders in patients with chronic medical diseases
36. Relationship of genetics, age, and physical fitness to daily energy expenditure and fuel utilization
37. Neurochemical systems of the hypothalamus: Control of feeding and drinking behaviour and water-electrolyte excretion
38. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat
39. Effect of amantadine on weight gain during olanzapine treatment
40. Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: Possible mechanisms of action
41. Hypothalamic dopamine and serotonin in the regulation of food intake
42. 2C serotonin receptors
43. Comparative effects of continuous infusion of m-CPP, Ro 60-0175 and D-fenfluramine on food intake, water intake, body weight and locomotor activity in rats
44. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity
45. 2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats
46. Atypical neuroleptics and glucose regulation
47. Behavioral and neuroendocrine characteristics of the night-eating syndrome
48. Divalproex and females with bipolar disorder: Reproductive and metabolic risks
49. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
50. Body weight gain after administration of antipsychotic drugs: Correlation with leptin, insulin and reproductive hormones
51. Body weight gain induced by antipsychotic drugs: Mechanisms and management
52. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders
53. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats
54. Mood stabilization and weight loss with topiramate
55. NMDA receptor coagonist glycine site: Evidence for a role in lateral hypothalamic stimulation of feeding
56. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis
57. Tumour necrosis factor, a key role in obesity?
58. Tumor necrosis factor (TNF)
59. Studies of endotoxin-induced decrease in lipoprotein lipase activity
60. Journey from cachexia to obesity by TNF
61. Tumor necrosis factor-α in sera of obese patients: Fall with weight loss
62. Plasma concentrations of soluble TNF-α receptors in obese subjects
63. Serum leptin levels increase rapidly after initiation of clozapine therapy
64. Leptin
65. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine
66. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine
67. Body weight and leptin plasma levels during treatment with antipsychotic drugs
68. Up-regulation of uncoupling proteins by β-adrenergic stimulation in L6 myotubes
69. 3-adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals
70. Role of the β(3)-adrenergic receptor and/or a putative β(4)-adrenergic receptor on the expression of uncoupling proteins and peroxisome proliferator-activated receptor-γ coactivator-1
71. Topiramate versus bupropion SR added to mood-stabilizer therapy for the depressive phase of bipolar disorder: A single-blind study
72. Topiramate as add-on treatment for patients with bipolar mania
73. Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: Alterations in hormones, neuropeptide, and uncoupling-protein mRNAs
74. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients